Switch theme
Sign up to access all valuation multiples
Cinclus Pharma Holding AB is a clinical stage pharmaceutical company developing a drug for the treatment of erosive gastroesophageal reflux diseases, and a dual therapy treatment with an antibiotic targeting Helicobacter pylori which is a bacteria that occurs in the gastric and duodenal mucosa. The Company’s main target population is patients suffering from severe eGERD, where there is a lack of satisfactory treatment options.
2017
13
LTM Revenue $5.4M
LTM EBITDA -$15.9M
$18.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cinclus Pharma Holding has a last 12-month revenue (LTM) of $5.4M and a last 12-month EBITDA of -$15.9M.
In the most recent fiscal year, Cinclus Pharma Holding achieved revenue of $0.5M and an EBITDA of -$16.2M.
Cinclus Pharma Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cinclus Pharma Holding valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.4M | XXX | $0.5M | XXX | XXX | XXX |
| Gross Profit | $5.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$15.9M | XXX | -$16.2M | XXX | XXX | XXX |
| EBITDA Margin | -295% | XXX | -3433% | XXX | XXX | XXX |
| EBIT | -$17.6M | XXX | -$17.4M | XXX | XXX | XXX |
| EBIT Margin | -327% | XXX | -3688% | XXX | XXX | XXX |
| Net Profit | -$15.0M | XXX | -$17.3M | XXX | XXX | XXX |
| Net Margin | -278% | XXX | -3669% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cinclus Pharma Holding's stock price is SEK 15 (or $2).
Cinclus Pharma Holding has current market cap of SEK 704M (or $72.6M), and EV of SEK 180M (or $18.6M).
See Cinclus Pharma Holding trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18.6M | $72.6M | XXX | XXX | XXX | XXX | $-0.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cinclus Pharma Holding has market cap of $72.6M and EV of $18.6M.
Cinclus Pharma Holding's trades at 39.3x EV/Revenue multiple, and -1.1x EV/EBITDA.
Equity research analysts estimate Cinclus Pharma Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cinclus Pharma Holding has a P/E ratio of -4.9x.
See valuation multiples for Cinclus Pharma Holding and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $72.6M | XXX | $72.6M | XXX | XXX | XXX |
| EV (current) | $18.6M | XXX | $18.6M | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 39.3x | XXX | XXX | XXX |
| EV/EBITDA | -1.2x | XXX | -1.1x | XXX | XXX | XXX |
| EV/EBIT | -1.1x | XXX | -1.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.9x | XXX | -4.2x | XXX | XXX | XXX |
| EV/FCF | -1.1x | XXX | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCinclus Pharma Holding's last 12 month revenue growth is 58%
Cinclus Pharma Holding's revenue per employee in the last FY averaged $36K, while opex per employee averaged $1.4M for the same period.
Cinclus Pharma Holding's rule of 40 is -3398% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cinclus Pharma Holding's rule of X is -151% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cinclus Pharma Holding and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 58% | XXX | 305% | XXX | XXX | XXX |
| EBITDA Margin | -295% | XXX | -3433% | XXX | XXX | XXX |
| EBITDA Growth | 38% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -3398% | XXX | -3375% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -151% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $36K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2984% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3788% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cinclus Pharma Holding acquired XXX companies to date.
Last acquisition by Cinclus Pharma Holding was XXXXXXXX, XXXXX XXXXX XXXXXX . Cinclus Pharma Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cinclus Pharma Holding founded? | Cinclus Pharma Holding was founded in 2017. |
| Where is Cinclus Pharma Holding headquartered? | Cinclus Pharma Holding is headquartered in Sweden. |
| How many employees does Cinclus Pharma Holding have? | As of today, Cinclus Pharma Holding has 13 employees. |
| Is Cinclus Pharma Holding publicy listed? | Yes, Cinclus Pharma Holding is a public company listed on STO. |
| What is the stock symbol of Cinclus Pharma Holding? | Cinclus Pharma Holding trades under CINPHA ticker. |
| When did Cinclus Pharma Holding go public? | Cinclus Pharma Holding went public in 2024. |
| Who are competitors of Cinclus Pharma Holding? | Similar companies to Cinclus Pharma Holding include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cinclus Pharma Holding? | Cinclus Pharma Holding's current market cap is $72.6M |
| What is the current revenue of Cinclus Pharma Holding? | Cinclus Pharma Holding's last 12 months revenue is $5.4M. |
| What is the current revenue growth of Cinclus Pharma Holding? | Cinclus Pharma Holding revenue growth (NTM/LTM) is 58%. |
| What is the current EV/Revenue multiple of Cinclus Pharma Holding? | Current revenue multiple of Cinclus Pharma Holding is 3.5x. |
| Is Cinclus Pharma Holding profitable? | Yes, Cinclus Pharma Holding is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cinclus Pharma Holding? | Cinclus Pharma Holding's last 12 months EBITDA is -$15.9M. |
| What is Cinclus Pharma Holding's EBITDA margin? | Cinclus Pharma Holding's last 12 months EBITDA margin is -295%. |
| What is the current EV/EBITDA multiple of Cinclus Pharma Holding? | Current EBITDA multiple of Cinclus Pharma Holding is -1.2x. |
| What is the current FCF of Cinclus Pharma Holding? | Cinclus Pharma Holding's last 12 months FCF is -$16.2M. |
| What is Cinclus Pharma Holding's FCF margin? | Cinclus Pharma Holding's last 12 months FCF margin is -301%. |
| What is the current EV/FCF multiple of Cinclus Pharma Holding? | Current FCF multiple of Cinclus Pharma Holding is -1.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
